You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Pearson CI, Luo A, Henning KA, et al
821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0821